b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30943495</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>06</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1423-0194</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>109</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Neuroendocrinology</Title>\n                <ISOAbbreviation>Neuroendocrinology</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>70-76</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000499382</ELocationID>\n            <Abstract>\n                <AbstractText>The behaviour of lactotroph tumours varies between benign tumours, those cured by treatment, and that of aggressive tumours, and carcinomas with metastasis. Identification of clinical, pathological and molecular factors is essential for the early identification of patients that may have such aggressive tumours. Plasma prolactin levels and tumour size and invasion, per se, are not prognostic factors. However, tumours appearing at a young age (&lt;20 years), especially in boys, and the presence of genetic predisposition have a poorer prognosis. In addition, lactotroph tumours in men differ from those in women, being larger, more often invasive, and resistant to dopamine agonists. They are also more often high-grade with a high risk of recurrence and malignancy. The expression of estrogen receptor \xce\xb1 is lower than in women and is closely correlated to aggressiveness. Proliferation markers (Ki-67 expression: \xe2\x89\xa53%, mitotic count n &gt; 2) are correlated to invasion and proliferation, but, taken alone, their prognostic value is debatable. Based on a 5-tiered clinicopathological classification, and taking into account invasion and proliferation, a grade 2b (aggressive) lactotroph tumour has a 20\xc3\x97 risk of progression compared to a grade 1a (benign) tumour. Moreover, lactotroph tumours are the second-most frequent aggressive and malignant tumour. Other factors, such as the expression of growth factors (vascular endothelial growth factor [VEGF] and epidermal growth factor [EGF]), the genes regulating invasion, differentiation and proliferation, adhesion molecules (E-cadherin), matrix metalloproteinase 9, and chromosome abnormalities (chromosomes 11, 19, and 1), have also been correlated with aggressiveness. Currently, clinical signs, a prognostic classification, and molecular and genetic markers may all help the clinician in the early identification of aggressive lactotroph tumours and enable stratification of their management.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 S. Karger AG, Basel.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Trouillas</LastName>\n                    <ForeName>Jacqueline</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 de Lyon 1, Universit\xc3\xa9 de Lyon, Lyon, France, jacqueline.trouillas@univ-lyon1.fr.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Facult\xc3\xa9 de M\xc3\xa9decine Lyon-Est, Lyon, France, jacqueline.trouillas@univ-lyon1.fr.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Delgrange</LastName>\n                    <ForeName>Etienne</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Service d\'Endocrinologie, CHU UCL Namur, Universit\xc3\xa9 catholique de Louvain, Mont-sur-Meuse, Belgium.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wierinckx</LastName>\n                    <ForeName>Anne</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 de Lyon 1, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Centre de Recherche en Canc\xc3\xa9rologie de Lyon (CRCL), INSERM U1052, CNRS UMR5286, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>ProfileXpert, SFR-Est, CNRS UMR-S3453, INSERM US7, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vasiljevic</LastName>\n                    <ForeName>Alexandre</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 de Lyon 1, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Facult\xc3\xa9 de M\xc3\xa9decine Lyon-Est, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Centre de Recherche en Canc\xc3\xa9rologie de Lyon (CRCL), INSERM U1052, CNRS UMR5286, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jouanneau</LastName>\n                    <ForeName>Emmanuel</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 de Lyon 1, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Centre de Recherche en Canc\xc3\xa9rologie de Lyon (CRCL), INSERM U1052, CNRS UMR5286, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Service de Neurochirurgie Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Burman</LastName>\n                    <ForeName>Pia</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Endocrinology, Sk\xc3\xa5ne University Hospital, Malm\xc3\xb6, University of Lund, Lund, Sweden.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Raverot</LastName>\n                    <ForeName>Gerald</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Universit\xc3\xa9 de Lyon 1, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Facult\xc3\xa9 de M\xc3\xa9decine Lyon-Est, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Centre de Recherche en Canc\xc3\xa9rologie de Lyon (CRCL), INSERM U1052, CNRS UMR5286, Universit\xc3\xa9 de Lyon, Lyon, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>D\xc3\xa9partment d\'Endocrinologie, Centre de R\xc3\xa9f\xc3\xa9rence pour les Maladies Hypophysaires Rares (HYPO), Groupement Hospitalier EST, Hospices Civils de Lyon, Bron, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>03</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Switzerland</Country>\n            <MedlineTA>Neuroendocrinology</MedlineTA>\n            <NlmUniqueID>0035665</NlmUniqueID>\n            <ISSNLinking>0028-3835</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015175" MajorTopicYN="N">Prolactinoma</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Aggressive tumours</Keyword>\n            <Keyword MajorTopicYN="Y">Lactotroph tumour</Keyword>\n            <Keyword MajorTopicYN="Y">Pituitary tumour</Keyword>\n            <Keyword MajorTopicYN="Y">Prognostic factors</Keyword>\n            <Keyword MajorTopicYN="Y">Prolactinoma</Keyword>\n            <Keyword MajorTopicYN="Y">Sex</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>5</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30943495</ArticleId>\n            <ArticleId IdType="pii">000499382</ArticleId>\n            <ArticleId IdType="doi">10.1159/000499382</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'